Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT06691087
Recruiting Not applicable

Sound Perception Study of Hearing-impaired People With Hearing Aids

NCT06691087 · tracked via the Priya Life Science France tracker
Sponsor
Institut Pasteur
Phase
Not applicable
Started
2025-04-22
Last updated
2026-03-31

Condition(s) studied

Auditory Perception

Investigational drug(s) / intervention(s)

Influence of the parameters of the sound timbre on the perception of a soundComplex sound scene comprehension testComplex sound scene comprehension test with hearing aids

Influence of the parameters of the sound timbre on the perception of a sound: The experiment consists of evaluating the sound level of n complex stimuli, then equalising them in loudness, in order to measure a loudness curve in function of timbre descriptors. The stimuli will then be listened to again in pairs. The task is there to compare the stimuli using a VAS to indicate how different the two sounds are.

Complex sound scene comprehension test: The experiment consists in identifying the parameters of the sound timbre that most disturb the understanding of complex sound scenes, by asking the participants to identify sounds whose timbre has been modified.

Complex sound scene comprehension test with hearing aids: The experiment will be identical to intervention 2. This time, the modification of the stimulus timbres will focus on the most problematic dimensional modifications, i.e. those where the difference between normal-hearing and hearing-impaired listeners is greatest. We will then modify the signal processing parameters of the hearing aid simulator (for example, the size of the averaging window or the gain balance of the filters), to observe their impact on the salience of certain stimuli.

Study summary

The aim of the ETERNEL project will be to study the influence of the perception of a single sound timbre on the understanding of a complex sound scene in hearing-impaired people with hearing aids. This will be done by quantifying the inability to manage a complex sound scene as a function of the timbre of the sounds making it up. The more a sound interferes with understanding the complex sound scene, the more salient that sound is considered to be. In this way, the investigators can determine which timbre dimensions make sounds particularly salient for the hearing impaired.

Eligibility

Sex
ALL
Min age
60 Years
Max age
75 Years
Healthy volunteers
Accepted
Inclusion Criteria: For all participants: * Age between 60 and 75 * Native French speaker * Have given their consent to take part in the study. * Declare that they have an active social life or hobbies that stimulate their cognitive abilities * Have a MOCA score above 26 * No tympano-ossicular dysfunction. * Voice in noise audiometry results showing normal results. For participants with impaired hearing : * Pure tone audiometry showing audiograms of type N3 or N4 and symmetrical between the two ears. * Report having experienced problems with abnormally prominent sound. For participants with normal hearing: \- Pure tone audiometry showing audiograms with losses of less than 30 dBHl. Exclusion Criteria: * Be under guardianship or curatorship, * Be deprived of liberty by judicial or administrative decision, or be under legal protection. * Bear the consequences of an ear infection and/or have a history of an ENT disease that permanently affects hearing or balance (vestibular schwannoma, Ménière's disease, sudden or fluctuating deafness, congenital hypoacusis).

Primary outcome measure(s)

  • Percentage of correct answers in melody comparison tasks in the hearing-impaired group compared with the normal-hearing group, — 3-hours

Trial sites (1)

FacilityCityRegionStatus
CeRIAH Paris France Recruiting

More Institut Pasteur trials in France

Development of a Battery of Audiological Tests for the Precision Diagnosis of Age-related Hearing Loss Recruiting
The Role of IL-23 in Chronic Inflammatory Disease: Exploring the Cellular and Molecular Targets of IL-23 Signaling in Peripheral and Axial Spondyloarthritis Recruiting
Study of Auditory Perception After Progressive Exposure to Aversive Sounds in People With Misophonia Starting soon
A Trial to Evaluate the Safety, Immunogenicity and the Optimal Dose of MOPEVAC-Las Vaccine Candidate Against Lassa Fever Recruiting
Description of the Immune Response to Yellow Fever Vaccination Recruiting

Other trials for the same condition

Users of Remote Conferencing and Compression of Sound Dynamics : Auditory Effects Recruiting
Auditory Localization in Schizophrenia Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06691087 on ClinicalTrials.gov ↗ ← All trials in France